PREDICTORS OF PREMATURE WITHDRAWAL AND DOSE REDUCTIONS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) PLUS RIBAVIRIN IN A LARGE, MULTINATIONAL, OPEN-LABEL EXPANDED ACCESS PROGRAM

Lee, Samuel S.;Horsmans, Yves;Roberts, Stuart K.;Berak, Hanna;Ferenci, Peter;et.al.
(2009) 60th Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases — Location: Boston (Ma) (30.October.2009)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 3.92 MB
Request a copy

Details

Authors
  • Lee, Samuel S.
    Author
  • Horsmans, YvesUCLouvain
    Author
  • Roberts, Stuart K.
    Author
  • Berak, Hanna
    Author
  • Ferenci, Peter
    Author
Show more
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Lee, S. S., Horsmans, Y., Roberts, S. K., Berak, H., Dusheiko, G. M., Harley, H., Gane, E. J., Husa, P., Han, K.-H., Hadziyannis, S. J., Heathcote, E. J., Messinger, D., Tietz, A., & Ferenci, P. (2009). PREDICTORS OF PREMATURE WITHDRAWAL AND DOSE REDUCTIONS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH PEGINTERFERON ALFA-2A (40KD) (PEGIFN alpha 2A) PLUS RIBAVIRIN IN A LARGE, MULTINATIONAL, OPEN-LABEL EXPANDED ACCESS PROGRAM. Hepatology, 50(4), 717A-717A. https://doi.org/10.1002/hep.22904 (Original work published 2009)